Healthcare | February 13, 2024
Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar
Launches collaborative centre for translational research in head and neck cancer
Launches collaborative centre for translational research in head and neck cancer
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
